Journey Medical Corporation to Report 2021 Year-End Financial Results and Provide… | News

SCOTTSDALE, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (NADSAQ:DERM), a commercial-stage pharmaceutical company focused on developing and commercializing pharmaceutical products for the treatment of dermatological diseases, today announces that it will release its 2021 year-end financial results after the close of U.S. financial markets on Wednesday, March 23, 2022. Journey Medical management will host a conference call and audio webcast on March 23 2022 at 4:30 p.m. ET.

To listen to the conference call, interested parties in the United States should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial approximately ten minutes before the scheduled start time and request to join the Journey Medical conference call. Attendees can register for the conference by accessing Please note that registered participants will receive their call number upon registration.

A live audio webcast can be accessed on the News & Events page of the Investors section of Journey Medical’s website,, and will remain available for replay for approximately 30 days following the conference call.

About Journey Medical Corporation Journey Medical Corporation (NASDAQ:DERM) (“Journey Medical”) is focused on the identification, acquisition, development and strategic commercialization of innovative and differentiated dermatology products through its sales model and effective marketing. The company currently markets nine products that help treat and cure common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience developing and marketing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). Journey is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the United States Securities and Exchange Commission (“SEC”). For more information about Journey Medical, visit

Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, all statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, execute and maintain financing and strategic agreements and relationships; risks related to the results of research and development activities; uncertainties related to preclinical and clinical trials; risks relating to the timing of the start and completion of clinical trials, including disruptions that may result from hostilities in Europe; our reliance on third-party vendors; risks related to the COVID-19 outbreak and its potential impact on the ability of our employees and consultants to complete work in a timely manner and our ability to obtain additional financing on favorable terms or not at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patents and intellectual property; competetion; and other risks described in our filings with the SEC. We expressly disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except where possible. required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be considered in its entirety, and all stipulations , conditions or covenants that apply to information given in any part of this press release should be read as applying mutatis mutandis to any other instance of such information appearing here.

Company Contacts: Jaclyn Jaffe and Bill Begien Fortress Biotech, Inc. (781) 652-4500 [email protected]

Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]

Copyright 2022 GlobeNewswire, Inc.

Luisa D. Fuller